Allergan, Inc.

Amgen Inc.

Allergan Sales, Inc.

Michael E Stern

Christopher S Schaumburg

David F Power

Michael E Garst

William Robert Carling

Karyn F Siemasko

Jianping Gao

Larry Allen Wheeler

Catherine Simone Victoire Frydrych

David Arthur Scowen

John E Donello

Daniel W Gil

Wendy M Blanda

Catherine C Turkel

Guang-Liang Jiang

Margery A Nicolson

Christopher S Schaumberg

Catherine Simone Victorire Frydrych

The present invention relates to formulations for administration to a joint fat pad of a subject, and to methods of treating joint pain, inflammation or disease. The disclosed formulations are intended for local administration to the joint fat pad to provide sustained release of a therapeutic agent to the joint cavity and surrounding tissues. The joint may be an arthritic joint, an injured joint or a surgically replaced joint. The therapeutic agent may be an analgesic agent, an anti-inflammatory agent or an immunosuppressive agent. A single administration of the formulation to the joint fat pad delivers a therapeutically effective amount of the therapeutic agent with reduced systemic exposure relative to a single systemic or a single intra-articular administration of a therapeutic dose of an identical therapeutic agent.

Joint fat pad formulations, and methods of use thereof

Methods of treating humans or animals having various conditions are disclosed which include administering a cyclosporine component. Among the conditions treated are dry mouth syndrome, verruciform xanthoma, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, cancer of the oral mucosa, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter pylori infection, duodenal ulcers, peptic ulcers, conditions affecting the uterus and appendicitis.

Therapeutic methods using cyclosporine components

Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.

Cyclosporin analogs

Disclosed herein is a method of treating dry eye with a KLK-13 antibody.

KLK-13 antibody inhibitor for treating dry eye

The present invention provides a method for the treatment of inflammatory diseases and/or conditions, e.g. allergic conjunctivitis, uveitis or phacoanaphylactic endophthalmitis in an eye of a mammal, said method comprising administering to said mammal in need of treatment a therapeutically effective amount of a novel cyclosporin A derivative selected from the group consisting of compounds represented by the formula: wherein Ris S-Alk-R wherein Alk is an alkylene linkage, preferably a methylene or poly methylene linkage, or a polyalkenylene linkage, e.g. a Cto Calkenylenyl linkage and R is a hydrogen or a unsubstituted or substituted hydrocarbyl group.

Cyclosporin derivatives for treating inflammatory diseases and conditions

Disclosed herein TPV1 is a method of treating ocular and systemic conditions by administering IL-10 and TPV134R polypeptides.

Methods of treating ocular and other diseases with Syn-134R polypeptide

Methods of treating humans or animals having dysfunctional oral mucosal tissue are disclosed which include topically administering cyclosporine A, salts thereof and/or mixtures thereof in an oral cavity of the human or animal.

Methods of treating humans or animals having rheumatoid arthritis are disclosed which include topically administering a therapeutically effective amount of a cyclosporine component to the human or animal, thereby treating the rheumatoid arthritis.

Methods for the therapeutic use of cyclosporine components

Methods of treating humans or animals having various conditions are disclosed which include administering a cyclosporinee component. Among the conditions treated are dry mouth syndrome, verruciform xanthoma, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, cancer of the oral mucosa, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter plylori infection, duodenal ulcers, peptic ulcers, conditions affecting the uterus and appendicitis.

Growing community of inventors

Mission Viejo, CA, United States of America

Michael E Stern